Company intelligence / Profile preview
Indaptus Therapeutics
New York City, New York, United Statesindaptusrx.com ↗
- Ownership
- Public · INDP
- Employees
- ~42
- Development stage
- Phase 2
01
Overview
Indaptus’ lead candidate Decoy20 has shown broad immune activation in multiple tumor types in Phase I trials with a favorable safety profile to date. The company has initiated higher-dose cohorts and plans combination studies with checkpoint inhibitors in early/mid–2025. No new clinically significant treatment-related adverse effects have been observed so far. Preclinical data support durable anti-tumor responses both as monotherapy and in combination settings.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Attenuated and killed non-pathogenic gram-negative bacteriaImmunotherapy agents (multi-PAMP bacterial therapies)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Merck Sharp & Dohme*LTS Lohmann Therapie-Systeme AG*
04
Financials
- Market cap
- $357.8M
- Total revenue
- $0
- Enterprise value
- $346.3M
Beyond the preview
Go deeper on Indaptus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indaptus Therapeutics.